Company profile
IRLAB Therapeutics
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Mesdopetam (IRL790)No recent activity | Phase 2 | D3Small molecule | Parkinson's Disease |
| Phase 2 | 5-HT/norepinephrineSmall molecule | Parkinson's Disease | |
| Phase 1/2 | Undisclosed / early pipelineSmall molecule | Parkinson's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.